Where is the live CopyMark page for USPTO serial 85202806?

The live record is at https://getcopymark.com/trademark/85202806. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns EPIGENE.COM?

According to the public USPTO record for serial number 85202806, the listed owner(s) include: Epigenesis Pharmaceuticals, LLC, Epigenesis Pharmaceuticals, LLC.

What is USPTO serial number 85202806?

Serial number 85202806 is the USPTO application identifier for the mark EPIGENE.COM. It is used to track examination, publication, and registration of this trademark.

Which trademark classes cover EPIGENE.COM?

The public record lists International Classes: 005. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: EPIGENE.COM Serial# 85202806 | status 606; last event UNDN | Trademark Info & Attorney Guidance

Q: What is the current status of EPIGENE.COM?

EPIGENE.COM (85202806) currently shows USPTO status code 606 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EPIGENE.COM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

Goods and services

Class	Description	Status	First use
005	medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ards), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (svt), adenosine stress tests, infantile respiratory distress syndrome (infantile rds), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (copd), as well as cancers including leukemias, lymphomas, carcinomas, and the like, e.g., colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, e.g., cancers which metastasized to the lung(s), breast, liver and prostate	ACTIVE	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Mar 9, 2012	UNDN	UNDELIVERABLE MAIL - NO ACTION TAKEN	—
Feb 13, 2012	MAB6	ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED	The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 13, 2012	ABN6	ABANDONMENT - NO USE STATEMENT FILED	The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 26, 2011	UNDN	UNDELIVERABLE MAIL - NO ACTION TAKEN	—
Jul 22, 2011	UNDN	UNDELIVERABLE MAIL - NO ACTION TAKEN	—
Jul 12, 2011	NOAM	NOA MAILED - SOU REQUIRED FROM APPLICANT	A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 18, 2011	NPUB	NOTICE OF PUBLICATION	—
May 17, 2011	PUBO	PUBLISHED FOR OPPOSITION	Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 5, 2011	WOAG	WITHDRAWAL OF ATTORNEY GRANTED	—
May 5, 2011	WOAR	TEAS WITHDRAWAL OF ATTORNEY RECEIVED	—
Apr 9, 2011	PREV	LAW OFFICE PUBLICATION REVIEW COMPLETED	—
Apr 9, 2011	ALIE	ASSIGNED TO LIE	—
Mar 29, 2011	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Mar 29, 2011	XAEC	EXAMINER'S AMENDMENT ENTERED	—
Mar 29, 2011	GNEN	NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED	—
Mar 29, 2011	GNEA	EXAMINERS AMENDMENT E-MAILED	—
Mar 29, 2011	CNEA	EXAMINERS AMENDMENT -WRITTEN	—
Mar 21, 2011	DOCK	ASSIGNED TO EXAMINER	—
Dec 31, 2010	MPMK	NOTICE OF PSEUDO MARK MAILED	—
Dec 30, 2010	NWOS	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	—
Dec 24, 2010	NWAP	NEW APPLICATION ENTERED	—

EPIGENE.COM